Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRA-PCI: Safety of Vorapaxar in Non-Emergent PCI
NCT00132912Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vorapaxar in coronary artery disease (CAD), sponsored by Merck & Co.. Started Aug 2005; status: completed.
02
Drugs
vorapaxar
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00132912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132912.